| abstract |
Methods and apparatus are disclosed for the measurement of lipocalin-2 in body fluid (including but not limited to blood, serum, plasma, urine, saliva, tear, etc) by an assay such as a immunoassay or an immunotest for (1) the prediction of risk of future cardiovascular diseases and (2) the determination of the likelihood that certain individuals will benefit to a greater o lesser extent from the use of certain treatments designed to prevent and/or treat cardiovascula diseases. |